US · Healthcare · Biotechnology
EPS came in at -1.04 against a street estimate of -0.51 — a miss of 103.9%.
Analysts rate Vanda Pharmaceuticals Inc a strong buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $11.75.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.66% |
| State Street Corp | 5.82% |
| AQR Capital Management LLC | 5.78% |
| Renaissance Technologies Corp | 5.69% |
| Vanguard Capital Management, LLC | 4.17% |
| AIGH Capital Management, LLC | 3.38% |
| Acadian Asset Management LLC | 3.17% |
| Dimensional Fund Advisors, Inc. | 2.86% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vanda Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.